QPPV.COM KNOWLEDGE ASSESSMENT

Product Quality Complaints and Pharmacovigilance: Where the Systems Meet

Test your understanding of the concepts covered by Product Quality Complaints and Pharmacovigilance: Where the Systems Meet.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A company receives a suspected defect report that may require market action, but the root cause is still under investigation. What is the soundest regulatory approach?

Defer notification until the investigation has established the root cause Assess and escalate the suspected defect under applicable requirements without treating root-cause confirmation as a prerequisite Submit an ICSR instead of a quality notification while testing continues Wait until all potentially affected units have been identified with certainty

Question 2 of 10 Several reports describe reduced therapeutic effect from one presentation, but initial product testing is inconclusive. What is the most appropriate approach?

Close both PV and Quality assessments because no defect has been demonstrated Assess applicable lack-of-efficacy reporting requirements and continue the quality investigation independently Classify every report as a confirmed manufacturing defect Treat lack of effect as a quality issue only, regardless of applicable PV criteria

Question 3 of 10 A quality investigation confirms a batch deviation that may affect the interpretation of an already submitted ICSR. What is the appropriate follow-up?

Leave the ICSR unchanged because it was submitted before the investigation ended Update the PV case with relevant findings while preserving the distinction between source information and investigation results Replace the original reporter account with the final quality conclusion Close the ICSR and retain the findings only in the quality file

Question 4 of 10 A case processor learns that a reported rash followed use of a device that is being investigated. Which reasoning is appropriate during initial PV assessment?

Defer medical assessment until Quality determines whether the device failed Assume the rash is unrelated because the defect is unconfirmed Assess the reported reaction on the available information while the defect investigation proceeds separately Code the suspected device failure as a confirmed adverse reaction

Question 5 of 10 Which records-and-linkage model best supports a case involving both a suspected reaction and an alleged product defect?

A single undifferentiated record that combines all decisions and timelines A quality record and an ICSR with distinct purposes, linked by stable identifiers An ICSR only, with quality evidence kept informally in email A quality record only until a confirmed defect is established

Question 6 of 10 A reporter alleges that a batch is defective, but no testing has been completed. How should the case record describe the batch status?

Record the batch as outside specification because the reporter made the allegation Record the allegation as reported and distinguish it from any confirmed investigation finding Remove the batch information until laboratory results are available Use internal product data to state that the batch is conforming, even if the investigation is pending

Question 7 of 10 Which evidence would best demonstrate that an organisation's quality–PV interface works effectively?

Separate written procedures exist, regardless of whether records show cross-functional communication Records show capture, parallel assessment, accountable owners, timely escalation, linked decisions and feedback of relevant findings Every complaint is entered as an ICSR to ensure that no safety information is missed The company has a single global deadline for all quality and PV actions

Question 8 of 10 Which statement best describes information access between PV and Quality when linked records contain patient information?

All Quality personnel should receive unrestricted access to identifiable patient data PV and Quality should exchange information relevant to their tasks using appropriate access controls and the minimum necessary information PV should receive no quality investigation findings because the records are separate Privacy controls can be disregarded whenever a complaint may affect product safety

Question 9 of 10 A suspected defect may create an immediate risk to patients, while the normal notification sequence has not yet been completed. What should take priority?

Waiting for the routine sequence to finish so that the record is complete Patient protection, with urgent action and authority communication in accordance with applicable procedures Completing the batch investigation before taking any market action Submitting an ICSR and treating that as sufficient interim action

Question 10 of 10 A product complaint later yields information identifying a patient and a suspected adverse reaction. What should the organisation do?

Keep the information exclusively in the quality file because that was the original intake route Have PV assess the new information under applicable case-processing rules and document relevant awareness dates Restart every clock from the date the quality investigation began Create an ICSR only if the quality team confirms a defect

QPPV.com

Product Quality Complaints and Pharmacovigilance: Where the Systems Meet

Cookie Settings